Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy
about
Planning for pandemic influenza: effect of a pandemic on the supply and demand for blood products in the United States.Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapyAntianemic Treatment of Cancer Patients in German Routine Practice: Data from a Prospective Cohort Study-The Tumor Anemia Registry.Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancerPatterns of erythropoiesis-stimulating agent use for chemotherapy-induced anemia in lung cancer: results of a retrospective Hungarian real-life clinical data analysis.The Role of Supportive Therapy in the Era of Modern Adjuvant Treatment - Current and Future Tools.Where does blood go? Prospective observational study of red cell transfusion in north England.Pharmacotherapy of anaemia in cancer patients.Audit of red cell transfusion.Standards of care for anemia management in oncology: focus on lung carcinoma.The efficacy of rHuEPO in cancer-related anaemia.Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia.Pharmacotherapy of chemotherapy-induced anaemia.The impact of hemoglobin level and transfusion on the outcomes of chemotherapy in gastric cancer patients.Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy.The impact of anaemia on outcome in cancer.Anaemia in cancer patients: pathophysiology, incidence and treatment.Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer.Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial.Safety considerations for erythropoietin treatment in patients with cancer.Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia.Recombinant human epoetin beta in the treatment of chemotherapy-related anemia.Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.Management of anemia in cancer patients.Indications for and complications of transfusion and the management of gynecologic malignancies.Changing indications for red cell transfusion from 2000 to 2004 in the North of England.Evaluation of the future supply and demand for blood products in the United Kingdom National Health Service.Cancer patients' willingness to pay for blood transfusions at home: results from a contingent valuation study in a French cancer network.Hemoglobin decline in chemotherapy patients prior to and after policy changes affecting use of erythropoiesis-stimulating agents: 2006-2009.An exploration of the influences on clinical decision making and the culture of blood transfusion practise in cancer-related anaemia using an ethnographic methodology.Impact of erythropoiesis-stimulating agents on red blood cell transfusion in Korea.Improvement in quality of life for cancer patients treated with epoetin alfa.Changing patient perceptions of the side effects of cancer chemotherapy.[Impact of anemia on chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer].
P2860
Q30361932-BDD46B03-044F-416E-A5C9-C29EEBDC9E85Q30749943-130BAEE5-C798-4B76-851D-DA15F6CA3860Q31056773-4A9E8136-26A8-4FC3-8CB2-45F6C3D36B73Q33344979-97216FAE-94FE-4011-80C7-62018D08B8F3Q33867969-76AE3CA6-8B88-4C71-88B4-5DEBEF655D38Q34095827-340167FD-23AF-4DB7-8503-1D086C7841AFQ34148352-84EC738F-CDD0-40A0-8B08-43896DF3A60AQ34515556-C9561729-04E9-4EC2-8062-30017478EBBBQ34609722-AD854F6C-FE86-4B9C-9CEC-6AC20FB6E8A3Q34810857-9A7BA6ED-7A03-4440-AB95-E3A403046371Q35096645-9A6B76D7-31E9-4CA6-A39A-AE70806DC4E0Q35144050-60C468FD-EFB0-44BE-B4F4-2E29698248F7Q35593977-D22698E1-D902-447D-8A00-7620A774D6ADQ35643973-7443F3F5-55E3-4009-920E-1B9CD82FE991Q35696941-5C4B3FE4-5F51-426E-8920-00CA7C16870FQ36027331-CAF6BD3E-12C8-4A07-9BA0-8944499961F6Q36310891-649F4ADA-E57D-4D3A-9D65-538E363DEB44Q36410646-9FC02ED4-D022-40E0-A8B5-C5278A2F3ABEQ36614017-AE8C07E9-F0C8-452E-B0FA-6639E646D615Q36689075-D190AE33-A8A3-4371-9FD1-656805970113Q37183442-E7F0E028-E824-4767-93E1-4571E4143856Q37230276-A8482BC1-0DA7-4C30-91B3-D62242B9D435Q37564558-680E6898-9857-4DF0-997D-129D34100AE9Q37861195-A1D492A8-4B8A-4E77-974A-38D97073054CQ39320771-5353A0E8-7513-413C-B2D6-D96C37E181CBQ40261062-EFFC5EE3-6AD4-4572-98AD-0755B62019D6Q40522291-68F44A1B-50C8-4C78-8D81-2F3481140209Q45031906-0DD1A168-B175-43D8-832C-37BCA4CB27F2Q46146660-5AC2C387-289F-4F6F-B431-1A3247DA2CD6Q47412056-511504EA-D2AE-4B01-AFAE-48CFD97D7EEAQ47582617-CE23E321-0AB9-45D0-B03B-009520011175Q52545201-E78DBBD0-9015-412B-95DD-C46C68DD186CQ53426696-2E331722-4608-468A-B090-97A611D5E5F6Q55430056-9AA7EC9E-8A14-4E0B-9BF2-EB66EBCE974C
P2860
Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Large-scale UK audit of blood ...... ceiving cytotoxic chemotherapy
@ast
Large-scale UK audit of blood ...... ceiving cytotoxic chemotherapy
@en
type
label
Large-scale UK audit of blood ...... ceiving cytotoxic chemotherapy
@ast
Large-scale UK audit of blood ...... ceiving cytotoxic chemotherapy
@en
prefLabel
Large-scale UK audit of blood ...... ceiving cytotoxic chemotherapy
@ast
Large-scale UK audit of blood ...... ceiving cytotoxic chemotherapy
@en
P2093
P2860
P356
P1476
Large-scale UK audit of blood ...... ceiving cytotoxic chemotherapy
@en
P2093
P2860
P2888
P356
10.1054/BJOC.1999.0883
P407
P577
2000-01-01T00:00:00Z
P5875
P6179
1039385702